By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

AbbVie 



      U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS

AbbVie (NYSE:ABBV) is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs approximately 25,000 people worldwide and markets medicines in more than 170 countries.


Key Statistics


Email:
Ownership: Public

Web Site: AbbVie
Employees:
Symbol: ABBV
 



Industry
Pharmaceutical






Company News
AbbVie (ABBV)'s Ongoing Research In Neuroscience And Oncology Will Be Featured At The 2015 American Academy of Neurology Annual Meeting 2/27/2015 9:46:23 AM
AbbVie (ABBV) Launches SigueElGuion.com To Educate Spanish-Speaking Americans About Hypothyroidism And The Importance Of Dialogue Between Patient And Healthcare Professional 2/26/2015 10:44:28 AM
AbbVie (ABBV) To Present At Cowen and Company 35th Annual Health Care Conference 2/25/2015 10:16:20 AM
Enanta Pharmaceuticals, Inc. Announces JAMA Publication Of Results From AbbVie (ABBV)’s Study Of VIEKIRA PAK™ (Ombitasvir, Paritaprevir, Ritonavir Tablets; Dasabuvir Tablets) In Chronic Hepatitis C Patients With HIV-1 Co-Infection (TURQUOISE-I) 2/23/2015 11:21:14 AM
Results from AbbVie (ABBV)'s Study Of VIEKIRA PAK (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) In Chronic Hepatitis C Patients With HIV-1 Co-Infection (TURQUOISE-I) Published Online In JAMA; Sub-Analyses To Be Presented At The Annual Conference On Retroviruses And Opportunistic Infections (CROI) 2/23/2015 9:33:09 AM
AbbVie (ABBV) Increases Quarterly Dividend 2/19/2015 11:53:55 AM
Enanta Pharmaceuticals, Inc. Announces AbbVie (ABBV) Submits New Drug Application To The Japanese Ministry Of Health, Labour And Welfare For Its Investigational, All-Oral, Treatment For Chronic Hepatitis C 2/12/2015 11:42:00 AM
AbbVie (ABBV) Submits New Drug Application In Japan For Its Investigational, All-Oral, Treatment For Chronic Hepatitis C 2/12/2015 6:43:40 AM
AbbVie (ABBV) Announces Top-Line Results From Phase 3 Study Of All-Oral Treatment For Hepatitis C In Japan 2/2/2015 7:41:03 AM
AbbVie (ABBV) Reports Fourth-Quarter And Full-Year 2014 Financial Results 1/30/2015 10:11:30 AM
12345678910...
//-->